Microbot Medical MBOT Balance Sheet Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $3.66M+13.7% | $3.91M+25.6% | $6.76M+1,182% | $4.14M+64.5% | $3.22M+177% | ||
| $68.84M+153% | $74.68M+3,070% | $73.45M+1,803% | $28.59M+615% | $27.17M+424% | ||
| $105K— | —— | —— | —— | —— | ||
| $2.26M+1,446% | $584K— | $146K— | $146K— | $146K— | ||
| $76.53M+150% | $79.82M+1,272% | $80.79M+1,517% | $32.89M+361% | $30.66M+338% | ||
| $188K+141% | $93K+16.3% | $78K-21.2% | $75K-38.5% | $78K-40.9% | ||
| $78.07M+153% | $81.54M+1,252% | $81.76M+1,470% | $33.13M+346% | $30.89M+319% | ||
| $1.09M+483% | $511K+210% | $509K+107% | $503K+183% | $186K+93.8% | ||
| $3.39M+78.9% | $3.42M+39.1% | $2.93M+114% | $2.73M+103% | $1.89M+60.0% | ||
| $3.96M+104% | $3.99M+59.5% | $3.54M+153% | $2.77M+101% | $1.94M+61.8% | ||
| 120M+100% | 120M+100% | 120M+100% | 120M+100% | 60M0.0% | ||
| -$107.76M-15.2% | -$104.09M-14.5% | -$100.62M-14.9% | -$97.05M-15.1% | -$93.55M-14.3% | ||
| $74.11M+156% | $77.55M+2,097% | $78.22M+1,954% | $30.36M+401% | $28.95M+369% | ||
| $78.07M+153% | $81.54M+1,252% | $81.76M+1,470% | $33.13M+346% | $30.89M+319% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Microbot Medical's total assets?
- Microbot Medical (MBOT) holds $78.1M in total assets, up 152.7% year over year.
- How much debt does Microbot Medical have?
- Microbot Medical carries $898.0K in total debt against $74.1M of shareholders' equity, a debt-to-equity ratio of 0.01.
- How much cash does Microbot Medical have?
- Microbot Medical holds $3.7M in cash and equivalents.
- Can Microbot Medical cover its short-term obligations?
- Its current ratio is 22.59 — current assets exceed current liabilities.
- Where does Microbot Medical's balance sheet data come from?
- Every line is extracted from Microbot Medical's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
